MedTrace Logo

A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma

NCT00498043 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2025-09-03

No results posted yet for this study

Summary

This Phase II study randomized R-ACVBP and R-CHOP as induction treatment in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI. The consolidation treatment is allocated according to the response to induction treatment assessed by PET after the 2nd and 4th induction cycles.

Conditions

  • Lymphoma, B-Cell
  • Lymphoma, Large-Cell, Diffuse

Interventions

DRUG

R-CHOP14 induction regimen

R-CHOP14 induction regimen

DRUG

R-ACVBP14 induction regimen

R-ACVBP14 induction regimen

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Bertrand Coiffier, MD · Hospices Civils de Lyon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00498043 on ClinicalTrials.gov